TickerTalks
Browse all tickers →
TickerTalks›$OTLK
OTOTLK

Outlook Therapeutics, Inc.

$OTLK·$65M·Biotechnology·Healthcare
$1.58-4.2%YTD+146.6%1Y-6.0%
Mentions · last 7 days
0
Price updated 12h ago
OTOTLK
Outlook Therapeutics, Inc.$OTLK
$1.58-4.24%0 posts
AI analysisFundamentalsVoices on X
Loading…

Sentiment on XAI analysisGenerated by AI from underlying data

Top X posts

How loud the X conversation is around $OTLK and which way it's leaning — read in seconds.

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment13 posts analyzed · as of 2026-06-18

Outlook Therapeutics is up 35% on FDA acceptance of the resubmitted BLA for ONS-5010/Lytenava in wet AMD as a Class 1 review with a PDUFA target action date of July 29, 2026. Analysts hiked the price target to $10 on submission, and the stock is up over 300% since the original alert with traders calling for $5 by the FDA date. Unusual call option volume reinforces the technical setup.

Read what X is saying about $OTLK

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • Volume context so you know if today's chatter is normal or unusual
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing ONS-5010, a bevacizumab-based treatment for wet age-related macular degeneration and retinal diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $OTLK.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition is the dominant structural driver — the 'next phase' of obesity drugs (oral formulations, differentiated mechanisms) is reshaping clinical bets for NVO competitors. Gene editing (CRSP, BEAM, NTLA, PRME) is transitioning from clinical to commercial-maturation phase with Casgevy scaling; oncology binary events (IBRX, ALLO, KURA) define the near-term calendar.

See how Biotechnology shapes $OTLK

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $OTLK's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Top industry ETF

$IBBiShares Biotechnology ETF
+2.4%YTD
+38.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
54.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-182%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-72.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
193.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
178%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-361%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.9Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 15, 2026$-0.16$-0.12-33.3%
Q4 2025Feb 17, 2026$-0.22$-0.17-29.4%
Q3 2025Dec 19, 2025$-0.22$-0.26+15.4%
Q2 2025Aug 14, 2025$-0.44$-0.42-4.8%
Next earningsThu, Aug 13·consensus EPS $-0.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$127K—-17.2%-11007%$-0.05$-7.8M
Q1 FY26$-1.2M—102%1116%$-0.38$-14.9M
Q4 FY25$-92K-154.0%1099%18864%$-0.38$-12.4M
Q3 FY25$1.5M—70.8%-1046%$-0.55$-11.9M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$14.3M$1.5M – $34.8M-$0.49-$0.52 – -$0.432
FY27$45.7M$13.2M – $107.7M-$0.23-$0.34 – -$0.133
FY28$22.8M$6.1M – $58.6M-$0.15-$0.46 – -$0.011
FY29$29.7M$7.9M – $76.2M-$0.12-$0.36 – -$0.011
FY30$30.3M$8.1M – $77.8M-$0.13-$0.39 – -$0.011

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.44%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+209.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+80.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 26.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today75.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.985-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Know if $OTLK is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Cluster buy5 insiders bought shares in the last 30 days.

Recent transactions

BuyJun 2Haddadin Yezan MuntherDirector29.0K sh$24KBuyMay 28Ghiath M. SukhtianDirector20.6M sh$12.0MBuyMay 27Sukhtian Faisal GhiathDirector122.2K sh$50KBuyMay 26Haddadin Yezan MuntherDirector34.0K sh$15KBuyMay 26Randy H ThurmanDirector5.0K sh$2KBuyMay 26Kurt J HilzingerDirector400.0K sh$177K
+ 1 other (1 expirelong) in window

See when $OTLK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentJun 1SC 13D/A
AI summary

A significant holder filed an amended Schedule 13D on Outlook Therapeutics, Inc. (OTLK) on June 1, 2026. Body unavailable — excerpt contains only the SEC cover-page header without filer name, updated stake, or amended intent.

424B5Prospectus supplement (offering)May 29424B5
AI summary

Outlook Therapeutics, Inc. (OTLK) filed a 424B5 prospectus supplement on May 29, 2026. Body unavailable — excerpt cuts off before the offering size, security type, price, or use of proceeds are disclosed.

424B5Prospectus supplement (offering)May 13424B5
AI summary

Outlook Therapeutics, Inc. (OTLK) filed a 424B5 prospectus supplement on May 13, 2026. Body unavailable — excerpt cuts off before the offering size, security type, price, or use of proceeds are disclosed.

8-KAgreement terminatedMay 138-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.02: Earnings release
AI summary

Outlook Therapeutics, Inc. (OTLK) filed a comprehensive 8-K on May 13, 2026 covering entry into a material definitive agreement (Item 1.01), termination of a material agreement (Item 1.02), and results of operations (Item 2.02). Body unavailable — excerpt cuts off before the specific agreement terms, terminated agreement details, and financial results are disclosed.

8-KUnregistered equity saleApr 238-K — Item 3.02: Unregistered equity sale · Item 8.01: Other event
AI summary

Outlook Therapeutics, Inc. (OTLK) reported unregistered sales of equity securities (Item 3.02) and other events (Item 8.01) in an 8-K filed April 23, 2026. Body unavailable — excerpt cuts off before the specific equity issuance terms or other-event details are disclosed.

424B5Prospectus supplement (offering)Apr 23424B5
AI summary

Outlook Therapeutics, Inc. (OTLK) filed a 424B5 prospectus supplement on April 23, 2026. Body unavailable — excerpt cuts off before the offering size, security type, price, or use of proceeds are disclosed.

424B5Prospectus supplement (offering)Mar 25424B5
424B5Prospectus supplement (offering)Mar 23424B5
+ 28 other (11 routine 8-Ks · 4 proxys · 4 8-Ks · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Reviewzacks.com·2d agoOutlook Therapeutics Eye Drug Review Returns To FDA For Fourth Timebenzinga.com·2d agoOutlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMDglobenewswire.com·3d agoOutlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMDglobenewswire.com·3d agoOutlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunityseekingalpha.com·13d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$ALT$IBRX$QURE$RXRX
Voices on X · top 13 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport